SCHEMBL1293232

SCHEMBL1293232

CNC(=O)c1cccc(F)c1Nc1ccnc(Nc2cc(CCO)nn2C)c1C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
NTRK1 P04629 1/20 0.36
MAPK3 P27361 1/20 0.36
MAPK1 P28482 1/20 0.36
MET P08581 9/20 0.34
INSR P06213 7/20 0.34
PIM1 P11309 1/20 0.33
BAD Q92934 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
ABL1 P00519 1/20 0.33
MAPK10 P53779 1/20 0.32
PTK2 Q05397 1/20 0.32
NUDT1 P36639 1/20 0.32
PDE10A Q9Y233 1/20 0.32
GPR52 Q9Y2T5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3473218 0.94 LMNA (0.40) LMNAPOLBNTRK1MAPK3MAPK1
SCHEMBL690957 0.82 MAPK3 (0.56) NTRK1MAPK3MAPK1JAK1TYK2
SCHEMBL12103291 0.80 MAPK3 (0.45) MAPK3MAPK1JAK2JAK1TYK2
SCHEMBL690644 0.79 MAPK3 (0.42) MAPK3MAPK1METINSRJAK1
SCHEMBL692085 0.75 MAPK3 (0.57) MAPK3MAPK1JAK1TYK2MAPK10
SCHEMBL1293044 0.74 MAPK3 (0.48) NTRK1MAPK3MAPK1JAK1TYK2
SCHEMBL12103304 0.73 MAPK1 (0.46) MAPK3MAPK1JAK2JAK1TYK2
SCHEMBL691314 0.72 MAPK3 (0.55) MAPK3MAPK1JAK1TYK2MAPK10
SCHEMBL12349650 0.72 JAK1 (0.43) MAPK3MAPK1METINSRJAK2
SCHEMBL1293095 0.72 MAPK1 (0.43) MAPK3MAPK1METINSRJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269774-A1 PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK GLAXOSMITHKLINE LLC 2011-11-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269774-A1 PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK PTK2, PAK1, CTTN LMNA 4034/4885POLB 2757/4885NTRK1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.